Larimar Therapeutics (LRMR) Total Current Liabilities (2013 - 2025)

Larimar Therapeutics' Total Current Liabilities history runs 13 years deep, the most recent figure standing at $64.8 million for Q4 2025.

• Quarterly Total Current Liabilities rose 166.03% year-over-year to $64.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $64.8 million (up 166.03% YoY) and the FY2025 annual result came in at $64.8 million, up 166.03% from the prior year.
• Total Current Liabilities was $64.8 million for Q4 2025 at Larimar Therapeutics, up from $45.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $64.8 million in Q4 2025 and bottomed at $6.6 million in Q3 2023.
• A 5-year average of $16.8 million and a median of $9.9 million in 2021 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Current Liabilities tumbled 30.38% — and 2024, when it surged 190.79%.
• Larimar Therapeutics' Total Current Liabilities stood at $8.8 million in 2021, then gained by 21.02% to $10.7 million in 2022, then fell by 11.2% to $9.5 million in 2023, then soared by 156.22% to $24.4 million in 2024, then soared by 166.03% to $64.8 million in 2025.
• Business Quant data shows LRMR's Total Current Liabilities at $64.8 million in Q4 2025, $45.1 million in Q3 2025, and $26.6 million in Q2 2025.